# Omvoh (mirikizumab-mrkz) was approved by the FDA in January 2025.

*biotech · news · 2026-05-05 · Benzinga*

## Key points

- Over 63.5% of Omvoh-treated UC patients maintained disease clearance after four years in LUCENT-3.
- Omvoh is the first interleukin-23p19 inhibitor to show sustained disease clearance in UC for four years.
- 61.3% of patients maintained endoscopic normalization plus remission for four years with Omvoh.
- FDA approved Omvoh for moderately to severely active Crohn's disease in January 2025.

**Companies:** Eli Lilly
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/news/health-care/26/05/52288104/eli-lilly-advances-as-inflammatory-bowel-disease-drug-reinforces-long-term-confidence)

---

Canonical: https://newsio.io/n/a37db37e-f6fd-4d1d-831b-1f6b87558b4d/omvoh-mirikizumab-mrkz-was-approved-by-the-fda-in-january-2025-eli-lillys-recent
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works